- 全部删除
您的购物车当前为空
MRTX-1257 是选择性的、可口服的不可逆共价KRAS G12C 抑制剂,其在 H358 细胞中测得 KRAS 依赖 ERK 磷酸化的IC50值为 900 pM。


为众多的药物研发团队赋能,
让新药发现更简单!
MRTX-1257 是选择性的、可口服的不可逆共价KRAS G12C 抑制剂,其在 H358 细胞中测得 KRAS 依赖 ERK 磷酸化的IC50值为 900 pM。
| 规格 | 价格 | 库存 | 数量 |
|---|---|---|---|
| 1 mg | ¥ 529 | In stock | |
| 5 mg | ¥ 1,250 | In stock | |
| 10 mg | ¥ 2,230 | In stock | |
| 25 mg | ¥ 3,880 | In stock | |
| 50 mg | ¥ 5,530 | In stock | |
| 100 mg | ¥ 7,520 | In stock | |
| 200 mg | ¥ 9,870 | In stock | |
| 1 mL x 10 mM (in DMSO) | ¥ 1,650 | In stock |
MRTX-1257 相关产品
| 产品描述 | MRTX-1257 is a selective, irreversible, and covalent inhibitor of KRAS G12C. It has an IC50 of 900 pM for KRAS dependent ERK phosphorylation in H358 cells. MRTX1257 demonstrated 31% bioavailability in the mouse, with free fraction exposures well above the cellular potency In a PK/PD experiment, 77% target engagement. |
| 体内活性 | MRTX-1257在3、10、30以及100 mg/kg剂量组显示持续的肿瘤退缩。以100 mg/kg的剂量每日给药可引起完全反应,在停药后70天以上仍维持该反应。在小鼠MIA PaCa-2 G12C移植模型中,MRTX-1257(1 mg/kg、3 mg/kg、10 mg/kg、30 mg/kg及100 mg/kg,口服,每日一次,连续30天)在所有剂量组均迅速抑制肿瘤生长。 |
| 分子量 | 565.71 |
| 分子式 | C33H39N7O2 |
| CAS No. | 2206736-04-9 |
| Smiles | CN1CCC[C@H]1COc1nc2CN(CCc2c(n1)N1CCN([C@@H](CC#N)C1)C(=O)C=C)c1cccc2cccc(C)c12 |
| 密度 | no data available |
| 颜色 | Yellow |
| 物理性状 | Solid |
| 存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | ||||||||||||||||||||||||||||||
| 溶解度信息 | DMSO: 35 mg/mL (61.87 mM), Sonication is recommended. | ||||||||||||||||||||||||||||||
| 体内实验配方 | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.54 mM), Sonication is recommended. 请按顺序添加溶剂,在添加下一种溶剂之前,尽可能使溶液澄清。如有必要,可通过加热、超声、涡旋处理进行溶解。工作液建议现配现用。以上配方仅供参考,体内配方并不是绝对的,请根据不同情况进行调整。 | ||||||||||||||||||||||||||||||
溶液配制表 | |||||||||||||||||||||||||||||||
DMSO
| |||||||||||||||||||||||||||||||
评论内容